Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.
International Journal Of Molecular Sciences
Curreli, Francesca F; Kwon, Young D YD; Nicolau, Isabella I; Burgos, Giancarla G; Altieri, Andrea A; Kurkin, Alexander V AV; Verardi, Raffaello R; Kwong, Peter D PD; Debnath, Asim K AK
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Antimicrobial Agents And Chemotherapy
Gartland, Margaret M; Cahn, Pedro P; DeJesus, Edwin E; Diaz, Ricardo Sobhie RS; Grossberg, Robert R; Kozal, Michael M; Kumar, Princy P; Molina, Jean-Michel JM; Mendo Urbina, Fernando F; Wang, Marcia M; Du, Fangfang F; Chabria, Shiven S; Clark, Andrew A; Garside, Louise L; Krystal, Mark M; Mannino, Frank F; Pierce, Amy A; Ackerman, Peter P; Lataillade, Max M
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
Aids (London, England)
Rose, Ronald R; Gartland, Margaret M; Li, Zhufang Z; Zhou, Nannan N; Cockett, Mark M; Beloor, Jagadish J; Lataillade, Max M; Ackerman, Peter P; Krystal, Mark M
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
Aids (London, England)
Rose, Ronald R; Gartland, Margaret M; Li, Zhufang Z; Zhou, Nannan N; Cockett, Mark M; Beloor, Jagadish J; Lataillade, Max M; Ackerman, Peter P; Krystal, Mark M
Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
The Journal Of Antimicrobial Chemotherapy
Gartland, Margaret M; Zhou, Nannan N; Stewart, Eugene E; Pierce, Amy A; Clark, Andrew A; Ackerman, Peter P; Llamoso, Cyril C; Lataillade, Max M; Krystal, Mark M
Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120.
Chemmedchem
Curreli, Francesca F; Belov, Dmitry S DS; Ahmed, Shahad S; Ramesh, Ranjith R RR; Kurkin, Alexander V AV; Altieri, Andrea A; Debnath, Asim K AK
Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
European Journal Of Medicinal Chemistry
Curreli, Francesca F; Belov, Dmitry S DS; Kwon, Young Do YD; Ramesh, Ranjith R; Furimsky, Anna M AM; O'Loughlin, Kathleen K; Byrge, Patricia C PC; Iyer, Lalitha V LV; Mirsalis, Jon C JC; Kurkin, Alexander V AV; Altieri, Andrea A; Debnath, Asim K AK
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.
Nature Chemical Biology
Pancera, Marie M; Lai, Yen-Ting YT; Bylund, Tatsiana T; Druz, Aliaksandr A; Narpala, Sandeep S; O'Dell, Sijy S; Schön, Arne A; Bailer, Robert T RT; Chuang, Gwo-Yu GY; Geng, Hui H; Louder, Mark K MK; Rawi, Reda R; Soumana, Djade I DI; Finzi, Andrés A; Herschhorn, Alon A; Madani, Navid N; Sodroski, Joseph J; Freire, Ernesto E; Langley, David R DR; Mascola, John R JR; McDermott, Adrian B AB; Kwong, Peter D PD
Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins.
Journal Of Virology
Zoubchenok, Daria D; Veillette, Maxime M; Prévost, Jérémie J; Sanders-Buell, Eric E; Wagh, Kshitij K; Korber, Bette B; Chenine, Agnès L AL; Finzi, Andrés A
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Antimicrobial Agents And Chemotherapy
Li, Zhufang Z; Zhou, Nannan N; Sun, Yongnian Y; Ray, Neelanjana N; Lataillade, Max M; Hanna, George J GJ; Krystal, Mark M
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
Antimicrobial Agents And Chemotherapy
Schader, Susan M SM; Colby-Germinario, Susan P SP; Quashie, Peter K PK; Oliveira, Maureen M; Ibanescu, Ruxandra-Ilinca RI; Moisi, Daniela D; Mespléde, Thibault T; Wainberg, Mark A MA
Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
Journal Of Virology
Nabatov, Alexey A AA; Pollakis, Georgios G; Linnemann, Thomas T; Kliphius, Aletta A; Chalaby, Moustapha I M MI; Paxton, William A WA